Dutch biotech scores €25M in small molecule bet to tackle lysosomal storage disorders

Natalie Grover

Reporter

While a host of biotech companies work on gene and enzyme replacement therapies for certain lysosomal storage disorders, a Dutch player is aiming to slot …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dutch biotech scores €25M in small molecule bet to tackle lysosomal storage disorders

Natalie Grover

Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Nvidia-backed Achira debuts, blending AI and physics to model molecules

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Dutch biotech scores €25M in small mol­e­cule bet to tack­le lyso­so­mal stor­age dis­or­ders

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Dutch biotech scores €25M in small molecule bet to tackle lysosomal storage disorders